questionsmedicales.fr
Enzymes et coenzymes
Enzymes
Isomerases
Intramolecular transferases
Phosphotransferases phosphomutases
Phosphotransferases phosphomutases : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Phosphotransferases phosphomutases : Questions médicales les plus fréquentes",
"headline": "Phosphotransferases phosphomutases : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Phosphotransferases phosphomutases : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-06-08",
"dateModified": "2025-03-05",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Phosphotransferases phosphomutases"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Intramolecular transferases",
"url": "https://questionsmedicales.fr/mesh/D019751",
"about": {
"@type": "MedicalCondition",
"name": "Intramolecular transferases",
"code": {
"@type": "MedicalCode",
"code": "D019751",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.399.520"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Bisphosphoglycerate mutase",
"alternateName": "Bisphosphoglycerate Mutase",
"url": "https://questionsmedicales.fr/mesh/D001731",
"about": {
"@type": "MedicalCondition",
"name": "Bisphosphoglycerate mutase",
"code": {
"@type": "MedicalCode",
"code": "D001731",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.399.520.750.250"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Phosphoglucomutase",
"alternateName": "Phosphoglucomutase",
"url": "https://questionsmedicales.fr/mesh/D010733",
"about": {
"@type": "MedicalCondition",
"name": "Phosphoglucomutase",
"code": {
"@type": "MedicalCode",
"code": "D010733",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.399.520.750.625"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Phosphoglyceromutase",
"alternateName": "Phosphoglycerate Mutase",
"url": "https://questionsmedicales.fr/mesh/D010736",
"about": {
"@type": "MedicalCondition",
"name": "Phosphoglyceromutase",
"code": {
"@type": "MedicalCode",
"code": "D010736",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.399.520.750.700"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Phosphotransferases phosphomutases",
"alternateName": "Phosphotransferases (Phosphomutases)",
"code": {
"@type": "MedicalCode",
"code": "D017875",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Stewart Shuman",
"url": "https://questionsmedicales.fr/author/Stewart%20Shuman",
"affiliation": {
"@type": "Organization",
"name": "Molecular Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA shumans@mskcc.org."
}
},
{
"@type": "Person",
"name": "Jean-Marc Jeckelmann",
"url": "https://questionsmedicales.fr/author/Jean-Marc%20Jeckelmann",
"affiliation": {
"@type": "Organization",
"name": "Institute of Biochemistry and Molecular Medicine, Medical Faculty, University of Bern, Bern, Switzerland."
}
},
{
"@type": "Person",
"name": "Balraj Doray",
"url": "https://questionsmedicales.fr/author/Balraj%20Doray",
"affiliation": {
"@type": "Organization",
"name": "Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO, USA."
}
},
{
"@type": "Person",
"name": "Benjamin C Jennings",
"url": "https://questionsmedicales.fr/author/Benjamin%20C%20Jennings",
"affiliation": {
"@type": "Organization",
"name": "Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO, USA."
}
},
{
"@type": "Person",
"name": "Wang-Sik Lee",
"url": "https://questionsmedicales.fr/author/Wang-Sik%20Lee",
"affiliation": {
"@type": "Organization",
"name": "Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO, USA."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Poly (ADP-ribose) polymerase (PARP) inhibitors as anticancer agents: An outlook on clinical progress, synthetic strategies, biological activity, and structure-activity relationship.",
"datePublished": "2024-05-31",
"url": "https://questionsmedicales.fr/article/38838546",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ejmech.2024.116535"
}
},
{
"@type": "ScholarlyArticle",
"name": "Oxomollugin, an oxidized substance in mollugin, inhibited LPS-induced NF-κB activation via the suppressive effects on essential activation factors of TLR4 signaling.",
"datePublished": "2024-04-02",
"url": "https://questionsmedicales.fr/article/38564154",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s11418-024-01798-y"
}
},
{
"@type": "ScholarlyArticle",
"name": "Impact of Virtual Reality-Based Group Activities on Activity Level and Well-Being Among Older Adults in Nursing Homes: Longitudinal Exploratory Study.",
"datePublished": "2024-03-29",
"url": "https://questionsmedicales.fr/article/38551635",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.2196/50796"
}
},
{
"@type": "ScholarlyArticle",
"name": "Identification of the Thermal Activation Network in Human 15-Lipoxygenase-2: Divergence from Plant Orthologs and Its Relationship to Hydrogen Tunneling Activation Barriers.",
"datePublished": "2024-03-28",
"url": "https://questionsmedicales.fr/article/38601784",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1021/acscatal.4c00439"
}
},
{
"@type": "ScholarlyArticle",
"name": "Response of antioxidant activity, active constituent and rhizosphere microorganisms of Salvia miltiorrhiza to combined application of microbial inoculant, microalgae and biochar under Cu stress.",
"datePublished": "2024-03-18",
"url": "https://questionsmedicales.fr/article/38508267",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.scitotenv.2024.171812"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Enzymes et coenzymes",
"item": "https://questionsmedicales.fr/mesh/D045762"
},
{
"@type": "ListItem",
"position": 3,
"name": "Enzymes",
"item": "https://questionsmedicales.fr/mesh/D004798"
},
{
"@type": "ListItem",
"position": 4,
"name": "Isomerases",
"item": "https://questionsmedicales.fr/mesh/D007535"
},
{
"@type": "ListItem",
"position": 5,
"name": "Intramolecular transferases",
"item": "https://questionsmedicales.fr/mesh/D019751"
},
{
"@type": "ListItem",
"position": 6,
"name": "Phosphotransferases phosphomutases",
"item": "https://questionsmedicales.fr/mesh/D017875"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Phosphotransferases phosphomutases - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Phosphotransferases phosphomutases",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-19",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Phosphotransferases phosphomutases",
"description": "Comment diagnostiquer une déficience en phosphomutases ?\nQuels tests sont utilisés pour évaluer l'activité des phosphomutases ?\nQuels symptômes peuvent indiquer un problème avec les phosphomutases ?\nLes tests génétiques sont-ils utiles pour le diagnostic ?\nQuelle imagerie peut aider à diagnostiquer des troubles liés aux phosphomutases ?",
"url": "https://questionsmedicales.fr/mesh/D017875?mesh_terms=Complement+Activation&page=1000#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Phosphotransferases phosphomutases",
"description": "Quels sont les symptômes d'une déficience en phosphomutases ?\nLes douleurs musculaires sont-elles liées aux phosphomutases ?\nPeut-on observer des anomalies métaboliques ?\nLes symptômes varient-ils selon l'âge ?\nY a-t-il des signes cliniques spécifiques à surveiller ?",
"url": "https://questionsmedicales.fr/mesh/D017875?mesh_terms=Complement+Activation&page=1000#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Phosphotransferases phosphomutases",
"description": "Peut-on prévenir les troubles liés aux phosphomutases ?\nY a-t-il des conseils diététiques pour prévenir les symptômes ?\nLes tests de dépistage sont-ils recommandés ?\nComment le suivi médical aide-t-il à la prévention ?\nLes vaccinations ont-elles un rôle dans la prévention ?",
"url": "https://questionsmedicales.fr/mesh/D017875?mesh_terms=Complement+Activation&page=1000#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Phosphotransferases phosphomutases",
"description": "Quels traitements sont disponibles pour les troubles liés aux phosphomutases ?\nLa thérapie génique est-elle une option ?\nLes médicaments peuvent-ils aider à gérer les symptômes ?\nY a-t-il des traitements expérimentaux en cours ?\nComment la nutrition influence-t-elle le traitement ?",
"url": "https://questionsmedicales.fr/mesh/D017875?mesh_terms=Complement+Activation&page=1000#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Phosphotransferases phosphomutases",
"description": "Quelles complications peuvent survenir avec une déficience en phosphomutases ?\nLes complications sont-elles réversibles ?\nComment les complications affectent-elles la qualité de vie ?\nY a-t-il des risques de complications à long terme ?\nLes complications peuvent-elles être prévenues ?",
"url": "https://questionsmedicales.fr/mesh/D017875?mesh_terms=Complement+Activation&page=1000#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Phosphotransferases phosphomutases",
"description": "Quels sont les facteurs de risque pour les troubles des phosphomutases ?\nL'environnement joue-t-il un rôle dans ces troubles ?\nLes habitudes alimentaires influencent-elles le risque ?\nY a-t-il des groupes à risque spécifique ?\nLe stress peut-il affecter le risque de troubles ?",
"url": "https://questionsmedicales.fr/mesh/D017875?mesh_terms=Complement+Activation&page=1000#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une déficience en phosphomutases ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests enzymatiques et des analyses biochimiques sont utilisés pour diagnostiquer."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'activité des phosphomutases ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests d'activité enzymatique in vitro mesurent la fonction des phosphomutases."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un problème avec les phosphomutases ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des troubles métaboliques, fatigue et douleurs musculaires peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les tests génétiques sont-ils utiles pour le diagnostic ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent identifier des mutations spécifiques liées aux phosphomutases."
}
},
{
"@type": "Question",
"name": "Quelle imagerie peut aider à diagnostiquer des troubles liés aux phosphomutases ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'imagerie par résonance magnétique (IRM) peut être utilisée pour évaluer les tissus."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une déficience en phosphomutases ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent fatigue, faiblesse musculaire et troubles de la croissance."
}
},
{
"@type": "Question",
"name": "Les douleurs musculaires sont-elles liées aux phosphomutases ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des douleurs musculaires peuvent survenir en raison de troubles métaboliques."
}
},
{
"@type": "Question",
"name": "Peut-on observer des anomalies métaboliques ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des anomalies dans le métabolisme des glucides et des lipides peuvent être présentes."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon l'âge ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent se manifester différemment selon l'âge et le développement."
}
},
{
"@type": "Question",
"name": "Y a-t-il des signes cliniques spécifiques à surveiller ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme l'hypoglycémie et des troubles neurologiques peuvent être observés."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les troubles liés aux phosphomutases ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention est difficile, mais un diagnostic précoce peut aider à gérer les symptômes."
}
},
{
"@type": "Question",
"name": "Y a-t-il des conseils diététiques pour prévenir les symptômes ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée et riche en nutriments peut aider à prévenir certains symptômes."
}
},
{
"@type": "Question",
"name": "Les tests de dépistage sont-ils recommandés ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests de dépistage peuvent être recommandés pour les familles à risque."
}
},
{
"@type": "Question",
"name": "Comment le suivi médical aide-t-il à la prévention ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi médical régulier permet de surveiller les symptômes et d'ajuster le traitement."
}
},
{
"@type": "Question",
"name": "Les vaccinations ont-elles un rôle dans la prévention ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les vaccinations ne préviennent pas directement les troubles enzymatiques, mais aident à la santé générale."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour les troubles liés aux phosphomutases ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement peut inclure des suppléments enzymatiques et des modifications diététiques."
}
},
{
"@type": "Question",
"name": "La thérapie génique est-elle une option ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La thérapie génique est en recherche pour traiter certaines déficiences enzymatiques."
}
},
{
"@type": "Question",
"name": "Les médicaments peuvent-ils aider à gérer les symptômes ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des médicaments peuvent être prescrits pour gérer les symptômes associés."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements expérimentaux en cours ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, plusieurs études cliniques explorent de nouveaux traitements pour ces troubles."
}
},
{
"@type": "Question",
"name": "Comment la nutrition influence-t-elle le traitement ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une nutrition adéquate peut améliorer la gestion des symptômes et le métabolisme."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec une déficience en phosphomutases ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent des troubles métaboliques graves et des problèmes neurologiques."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais d'autres peuvent être permanentes."
}
},
{
"@type": "Question",
"name": "Comment les complications affectent-elles la qualité de vie ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications peuvent réduire la qualité de vie en limitant les activités quotidiennes."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de complications à long terme ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des risques de complications à long terme existent, nécessitant un suivi médical."
}
},
{
"@type": "Question",
"name": "Les complications peuvent-elles être prévenues ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être évitées par un traitement précoce et un suivi régulier."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour les troubles des phosphomutases ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents familiaux et certaines mutations génétiques augmentent le risque."
}
},
{
"@type": "Question",
"name": "L'environnement joue-t-il un rôle dans ces troubles ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des facteurs environnementaux peuvent influencer l'expression des gènes liés aux phosphomutases."
}
},
{
"@type": "Question",
"name": "Les habitudes alimentaires influencent-elles le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une mauvaise alimentation peut exacerber les symptômes et augmenter le risque de complications."
}
},
{
"@type": "Question",
"name": "Y a-t-il des groupes à risque spécifique ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les personnes avec des antécédents familiaux de troubles métaboliques sont à risque accru."
}
},
{
"@type": "Question",
"name": "Le stress peut-il affecter le risque de troubles ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress peut aggraver les symptômes et influencer le métabolisme."
}
}
]
}
]
}
Poly (ADP-ribose) polymerase (PARP) is considered an essential component in case of DNA (Deoxyribonucleic acid) damage, response by sensing DNA damage and engaging DNA repair proteins. Those proteins ...
Oxomollugin is a degraded product of mollugin and was found to be an active compound that inhibits LPS-induced NF-κB activation. In this study, we investigated the inhibitory activity of oxomollugin, ...
In addition to illness, inactivity is a risk factor for high mortality in nursing homes. Using innovative technology, such as virtual reality (VR), for meaningful group activities could provide new op...
In this study, we examined whether VR-based group activities can have a positive impact on activity level and group interaction among older adults living in nursing homes....
We conducted a longitudinal study and provided VR interventions as a group activity once a week for 4 consecutive weeks in nursing homes. Participants were recruited based on the experience of the nur...
The results focus on a total of 84 older adults from 14 nursing homes who completed at least 3 VR interventions. The results indicate that several psychosocial capacities among the older adults improv...
This study provides a novel and naturalistic perspective, offering new insights into the use of VR in nursing homes. The VR intervention was well accepted and fulfilled the aim of enhancing capacity a...
The oxidation of polyunsaturated fatty acids by lipoxygenases (LOXs) is initiated by a C-H cleavage step in which the hydrogen atom is transferred quantum mechanically (i.e., via tunneling). In these ...
Salvia miltiorrhiza, a widely used medicinal herb renowned for its properties in promoting blood circulation, removing blood stasis and alleviating pain, is currently facing quality degradation due to...
Regular participation in physical activity (PA) benefits children's health and well-being and protects against the development of unhealthy body weight. A key factor in children's PA participation is ...
This study was conducted in accordance with the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) statement. We searched seven electronic databases (PubMed/Medline, Embase, ER...
Twenty-seven studies were included in the review, and twenty-six studies were included in the meta-analysis. A wide range of PA intervention approaches (e.g., single component or multicomponent) withi...
This study uniquely contributes to the literature through its primary focus on the effectiveness of PA interventions on elementary children's MC. This review emphasizes the importance of customizing C...
Active travel and school settings are considered ideal for promoting physical activity. However, previous research suggests limited effect of school-based interventions on overall physical activity le...
We analyzed data from 1370 pupils in the 9th-grade participating in the cluster RCT; the School In Motion (ScIM) project. Intervention schools (n = 19) implemented 120 min of class-scheduled physical ...
During the intervention period, most participants maintained their travel habits. In total, 91% of pupils maintained their travel mode to school. Only 6% of pupils switched to motorized travel and 3% ...
The extra school-based physical activity does not seem to affect rates of active travel among adolescents in the ScIM project....
Clinicaltrials.gov ID nr: NCT03817047. Registered 01/25/2019' retrospectively registered'....
Macroautophagy/autophagy contributes to maladaptive kidney repair by inducing pro-fibrotic factors such as FGF2 (fibroblast growth factor 2), but the underlying mechanism remains elusive. Here, we sho...
This study aimed to investigate the possible role of galectin-3 in epilepsy and further explore its underlying mechanisms....
Sprague-Dawley rats were intraperitoneally injected with 30 mg/kg pilocarpine to induce an animal model of epilepsy. To inhibit galectin-3, the epilepsy model of rats was intraperitoneally injected wi...
A higher expression of galectin-3 was observed in the hippocampal CA1 regions of epilepsy rats than in sham rats. Inhibition of galectin-3 by administration of TD139 improved the severity of the seizu...
Galectin-3 activates the NLRP3/pyroptosis signaling pathway to promote microglial activation and neuroinflammation during epilepsy disease progression....
[This retracts the article DOI: 10.7150/ijbs.46986.]....